使用当代心肌肌钙蛋白I检测验证(仅肌钙蛋白)曼彻斯特急性冠脉综合征决策辅助工具
本研究为英国Stepping Hill医院前瞻性诊断队列的二次分析,纳入405例疑似心脏性胸痛需排除ACS的患者,所有患者至少在症状高峰后12小时检测高敏肌钙蛋白T。主要终点为ACS诊断,定义为现患急性心肌梗死或30天内主要不良心脏事件(死亡、AMI或冠状动脉血运重建)。405例中76例(18.8%)发生ACS。MACS与T-MACS的C统计量相似(均为0.94,p=0.36),敏感性差异为1.3%(95%CI -1.3至3.9%,p=1.00),但T-MACS特异性显著更高(差异16.7%,95%CI 14.6-18.9%,p<0.0001)。T-MACS和MACS分别可使36.3%和22.5%的患者立即离院。结论认为两者均能有效排除ACS,可减少不必要的住院。
要点
- 在405例疑似ACS胸痛患者中,T-MACS特异性较MACS显著提高16.7%(95%CI 14.6-18.9%,p<0.0001),可使36.3%患者立即离院,而MACS为22.5%。
- MACS与T-MACS的C统计量均为0.94(p=0.36),敏感性差异1.3%(95%CI -1.3至3.9%,p=1.00),排除ACS效能相当。
- MACS分类为「极低风险」的患者中无ACS发生,T-MACS「极低风险」患者中1例(0.7%)发生ACS。
- 所有患者均至少在症状高峰后12小时检测高敏肌钙蛋白T,并使用Siemens Advia Centaur心肌肌钙蛋白I检测进行验证。
适用人群与场景
- 英国Stepping Hill医院前瞻性诊断队列中因疑似心脏性胸痛就诊于急诊科、需排除ACS的患者。
诊断标准与关键阈值
- ACS诊断定义为现患急性心肌梗死(AMI)或30天内发生主要不良心脏事件(死亡、AMI或冠状动脉血运重建)。
研究设计与关键结果
- 研究类型为前瞻性诊断队列研究的二次分析,纳入405例患者,76例(18.8%)发生ACS。
- MACS与T-MACS的C统计量均为0.94(p=0.36),敏感性差异1.3%(95%CI -1.3至3.9%,p=1.00)。
- T-MACS特异性较MACS显著提高16.7%(95%CI 14.6-18.9%,p<0.0001)。
- T-MACS和MACS分别可使36.3%和22.5%的患者立即离院。
- MACS分类为「极低风险」的患者中无ACS发生,T-MACS「极低风险」患者中1例(0.7%)发生ACS。
证据类型、等级与局限
- 证据类型:前瞻性诊断队列研究的二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为MACS和T-MACS均可有效排除ACS,即使使用当代肌钙蛋白I检测,可用于减少不必要的住院。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: The Manchester Acute Coronary Syndromes (MACS) decision aid can 'rules in' and 'rule out' acute coronary syndromes (ACS) by combining a patient's symptoms with the results of a single blood test taken at the time of arrival in the Emergency Department (ED). The original model (MACS) included two biomarkers: high sensitivity cardiac troponin T (hs-cTnT) and heart-type fatty acid binding protein (h-FABP). A refined model without h-FABP was found to have comparable sensitivity but greater specificity. We sought to validate MACS and T-MACS using the contemporary Siemens Advia Centaur cardiac troponin I assay to increase usability in practice.
METHODS: This is a secondary analysis from prospective diagnostic cohort study at Stepping Hill Hospital, United Kingdom. Patients presenting with chest pain of suspected cardiac nature warranting rule out for ACS were included. All patients underwent hs-cTnT testing at least 12h after peak symptoms. The primary outcome was a diagnosis of ACS, defined as either prevalent acute myocardial infarction (AMI) or incident major adverse cardiac events (death, AMI or coronary revascularization) within 30days.
RESULTS: Of 405 included patients, 76 (18.8%) had ACS. MACS and T-MACS had similar C-statistics (0.94 for each, p=0.36) and sensitivity (difference 1.3%, 95% CI -1.3 to 3.9%, p=1.00) but T-MACS had significantly greater specificity (difference 16.7%, 95% CI 14.6-18.9%, p<0.0001). T-MACS and MACS would have allowed 36.3% and 22.5% patients to be immediately discharged respectively. Of patients classified as 'very low risk', none had ACS when MACS was used compared to one (0.7%) with T-MACS.
CONCLUSION: Both MACS and T-MACS effectively ruled out ACS even with a contemporary troponin I assay and could be used to reduce unnecessary hospital admissions.
参考来源
- Va Den Berg P, Burrows G, Lewis P, et al. Validation of the (Troponin-only) Manchester ACS decision aid with a contemporary cardiac troponin I assay. Am J Emerg Med. 2017. PMID: 29079376. doi:10.1016/j.ajem.2017.09.032
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。